FDA
-
-
-
-
-
-
-
Rezolute (RZLT) Reiterated at Neutral by Cantor Fitzgerald After FDA Meeting
-
-
-
-
-
-
-
Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Rezolute Inc. (RZLT) Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
-
-
-
-
-
-
-
Rezolute Inc. (RZLT) Provides Update on its Phase 3 sunRIZE Study of Ersodetug
-
-
-
-
-
-
-
FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
-
-
-
-
-
-
-
Jones Trading Reiterates Buy Rating on Rezolute (RZLT) following FDA lift of clinical hold on RZ358
-
322,245 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

